Thailand HIV Therapeutics Market Analysis Report [2022-30]

Thailand HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Thailand HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Siam Pharmaceuticals, BSP Pharmaceuticals, and Government Pharmaceutical Organization. The market is driven by the prevalence of HIV infections and the healthcare infrastructure of the country. The HIV therapeutics market in Thailand is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10THPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Dr. Vishwa Modhia

Buy Now

Thailand HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Thailand HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Thailand is a nation in Southeast Asia that borders the Andaman Sea and the Gulf of Thailand. In 2021, Thailand had a 1% adult prevalence of HIV/AIDS, placing it in 38th place globally. The number of HIV/AIDS-related deaths in Thailand reached 13,922 in 2020, or 3.13% of all fatalities, according to the most recent WHO data.

Thailand is ranked 46th in the world with an age-adjusted death rate of 17.53 per 100,000 people. In 2019, Thailand's GDP was allocated to healthcare at 4.4%. Thailand is the only country from Southeast Asia (SEA) to rank in the top fifteen, coming in fourth place overall among the 118 countries in the International Monetary Fund's (IMF) dataset for medical tourism spending

Market Dynamics

Market Growth Drivers

By 2028, the Thai government wants to make Phuket a premier destination for medical travelers. Phuket intends to build a complex called "Medical Plaza" for international medical travel.

Market Restraints

In spite of Thailand's successful approach to the prevention of HIV infection, about 1 Mn people are infected with HIV. The cost of effective treatment regimens containing three drugs ranges from $538 to $776 per month, making antiretrovirals unaffordable for the majority of Thais.

Competitive Landscape

Key Players

Government Pharmaceutical Organization (GPO) (THA)
BSP Pharmaceuticals (THA)
Siam Pharmaceuticals (THA)
Gilead Sciences
Pfizer
AstraZeneca
Novartis
GlaxoSmithKline

Recent Notable Updates

September 2022: Thailand has ambitious plans to end new HIV infections by the year 2030, and as part of those plans, they're launching an online program to improve public access to HIV testing and HIV/AIDS treatment. For the 2023 fiscal year project, the National Health Security Office (NHSO) has set aside $120 Mn. In order to provide people living with HIV/Aids with the ongoing care they need, the program will offer free HIV screening tests, consultation, treatment, and related laboratory testing.

Healthcare Regulations and Reimbursement Policies

The Thai Food and Drug Administration (FDA) is the primary regulating body for HIV therapeutics in Thailand. All medications produced and marketed in Thailand, including antiretroviral medications used to treat HIV, must be authorized by and subject to oversight by the Thai FDA. The Thai FDA sets requirements for the quality, safety, and efficacy of medicines and regularly inspects pharmaceutical suppliers to make sure these requirements are being met.

The National Health Security Office (NHSO) of the Thai Ministry of Public Health offers free antiretroviral (ARV) treatment to qualified patients. At specific government hospitals, patients who are covered by the NHSO can get their ARV medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.